Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells

Cancer Research

Volumn 67, Issue 17, 2007, Pages 8180-8187

  Beckers, Annelies ^a   Organe, Sophie ^a   Timmermans, Leen ^a   Scheys, Katryn ^a   Peeters, Annelies ^a   Brusselmans, Koen ^a   Verhoeven, Guido ^a   Swinnen, Johannes V ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; PALMITIC ACID; POLYKETIDE; SORAPHEN A; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CULTURE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; MALE; MYXOCOCCALES; PRIORITY JOURNAL; PROSTATE CANCER;

ACETYL-COA CARBOXYLASE; APOPTOSIS; AUTOPHAGY; CELL DEATH; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS; HUMANS; MACROLIDES; MALE; NEOPLASMS; PALMITIC ACID; PHOSPHOLIPIDS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34548580317     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0389     Document Type: Article

References (47)

1. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006;9:358-65.
2. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-80.
3. Wakil SJ, Stoops JK, Joshi VC. Fatty acid synthesis and its regulation. Annu Rev Biochem 1983;52:537-79.
4. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997;3:2115-20.
5. Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer 2000;88:176-9.
6. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000;31:1068-73.
7. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002;98:19-22.
8. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000;16:202-8.
9. Pizer ES, Jackisch C, Wood FD, Pasternack GR, Davidson NE, Kuhajda FP. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996;56:2745-7.
10. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996;56:1189-93.
11. Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 1998;58:4611-5.
12. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000;97:3450-4.
13. Li JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 2001;61:1493-9.
14. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 2003;106:856-62.
15. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 2004;64:2070-5.
16. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003;63:3799-804.
17. Abu-Elheiga L, Jayakumar A, Baldini A, Chirala SS, Wakil SJ. Human acetyl-CoA carboxylase: characterization, molecular cloning, and evidence for two isoforms. Proc Natl Acad Sci U S A 1995;92:4011-5.
18. Widmer J, Fassihi KS, Schlichter SC, et al. Identification of a second human acetyl-CoA carboxylase gene. Biochem J 1996;316:915-22.
19. Carretero J, Medina PP, Blanco R, et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007;26:1616-25.
20. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004;101:3329-35.
21. Moreau K, Dizin E, Ray H, et al. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 2006;281:3172-81.
22. Magnard C, Bachelier R, Vincent A, et al. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 2002;21:6729-39.
23. Pizer ES, Thupari J, Han WF, et al. Malonylcoenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000;60:213-8.
24. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 2001;285:217-23.
25. Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-a gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005;65:6719-25.
26. Chajes V, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase a is essential to breast cancer cell survival. Cancer Res 2006;66:5287-94.
27. Bedorf N, Schomburg D, Gerth K, Reichenbach H, Höfle G. Isolation and structure elucidation of soraphen A1, a novel antifungal macrolide from Sorangium cellulosum. Liebigs Ann Chem 1993;1017-21.
28. Gerth K, Bedorf N, Irschik H, Hofle G, Reichenbach H. The soraphens: a family of novel antifungal compounds from Sorangium cellulosum (Myxobacteria). I. Soraphen A1 a: fermentation, isolation, biological properties. J Antibiot (Tokyo) 1994;47:23-31.
29. Pridzun L, Sasse F, Reichenbach H. Inhibition of fungal acetyl-CoA carboxylase: A novel target discovered with the myxobacterial compound soraphen. In: Dixon GK, Copping LG, Hollomon DW, editors. Antifungal agents. Oxford: BIOS Scientific Publishers Ltd.; 1995. p. 99-109.
30. Vahlensieck HF, Pridzun L, Reichenbach H, Hinnen A. Identification of the yeast ACC1 gene product (acetyl-CoA carboxylase) as the target of the polyketide fungicide soraphen A. Curr Genet 1994;25:95-100.
31. Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L. A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product. Mol Cell 2004;16:881-91.
32. Weatherly SC, Volrath SL, Elich TD. Expression and characterization of recombinant fungal acetyl-CoA carboxylase and isolation of a soraphen-binding domain. Biochem J 2004;380:105-10.
33. Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W, Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996;137:4468-74.
34. Van Veldhoven PP, Bell RM. Effect of harvesting methods, growth conditions and growth phase on diacylglycerol levels in cultured human adherent cells. Biochim Biophys Acta 1988;959:185-96.
35. Van Veldhoven PP, Meyhi E, Mannaerts GP. Enzymatic quantitation of cholesterol esters in lipid extracts. Anal Biochem 1998;258:152-5.
36. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8.
37. Biederbick A, Kern HF, Elsasser HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol 1995;66:3-14.
38. Niemann A, Takatsuki A, Elsasser HP. The lysosomotropic agent monodansylcadaverine also acts as a solvent polarity probe. J Histochem Cytochem 2000;48:251-8.
39. Munafo DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 2001;114:3619-29.
40. Kiorpes TC, Hoerr D, Ho W, Weaner LE, Inman MG, Tutwiler GF. Identification of 2-tetradecylglycidyl coenzyme A as the active form of methyl 2-tetradecylglycidate (methyl palmoxirate) and its characterization as an irreversible, active site-directed inhibitor of carnitine palmitoyltransferase A in isolated rat liver mitochondria. J Biol Chem 1984;259:9750-5.
41. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003;302:898-903.
42. Swinnen JV, Verhoeven G. Androgens and the control of lipid metabolism in human prostate cancer cells. J Steroid Biochem Mol Biol 1998;65:191-198.
43. Halvorson DL, McCune SA. Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 1984;19:851-856.
44. Otto DA, Chatzidakis C, Kasziba E, Cook GA. Reciprocal effects of 5-(tetradecyloxy)-2-furoic acid on fatty acid oxidation. Arch Biochem Biophys 1985;242:23-31.
45. Harwood HJ, Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 2005;9:267-81.
46. Kinlaw WB, Quinn JL, Wells WA, Roser-Jones C, Moncur JT. Spot 14: A marker of aggressive breast cancer and a potential therapeutic target. Endocrinology 2006;147:4048-55.
47. Harwood HJ, Jr. Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome. Curr Opin Investig Drugs 2004;5:283-9.